Cullinan Therapeutics (CGEM) Profit After Tax (2020 - 2026)

Cullinan Therapeutics' Profit After Tax history runs 7 years deep, the most recent figure standing at -$50.6 million for Q1 2026.

• In Q1 2026, Profit After Tax fell 4.23% year-over-year to -$50.6 million; the TTM figure through Mar 2026 stood at -$221.9 million (down 24.17% YoY), while the FY2025 annual figure was -$219.9 million, down 31.36% from the prior year.
• Profit After Tax for Q1 2026 stood at -$50.6 million, roughly flat from -$50.7 million in the prior quarter.
• The five-year high for Profit After Tax was $174.1 million in Q2 2022, with the low at -$70.1 million in Q2 2025.
• The 5-year median for Profit After Tax is -$40.6 million (2024), against an average of -$28.6 million.
• Peak annual rise in Profit After Tax reached 1158.85% in 2022, while the deepest fall reached 1008.53% in 2022.
• Cullinan Therapeutics' Profit After Tax stood at -$28.8 million in 2022, then advanced by 11.24% to -$25.6 million in 2023, then sank by 86.39% to -$47.6 million in 2024, then declined by 6.43% to -$50.7 million in 2025, then increased by 0.31% to -$50.6 million in 2026.
• Business Quant data shows CGEM's Profit After Tax at -$50.6 million in Q1 2026, -$50.7 million in Q4 2025, and -$50.6 million in Q3 2025.